Navigation Links
Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide
Date:11/25/2013

DUBLIN, November 25, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/q99tkv/ziopharm) has announced the addition of the "Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


The rationale to develop a stable formulation of palifosfamide is strong: it is the active metabolite of ifosfamide, a well-established alkylating chemotherapy agent. Palifosfamide may spare patients from the toxicities of two other inactive ifosfamide metabolites while retaining its anti-tumor activity. A phase III trial of palifosfamide in first line soft tissue sarcoma (PICASSO III) is underway with progression-free survival results expected later this year. In this report, we review the evidence supporting palifosfamide's development, the likelihood of clinical trial success, key regulatory hurdles as well as the commercial opportunity.

Key Topics Covered:

INTRODUCTION

1. Sarcomas
2. Treatment and prognosis of soft tissue sarcoma
3. Treatment of advanced or metastatic soft tissue sarcoma



PALIFOSFAMIDE

1. Palifosfamide as a single-agent
2. Palifosfamide in combination with doxorubicin
3. Phase I
4. Phase II
5. On-going phase III
6. Phase III trial in small cell lung cancer



CLINICAL AND REGULATORY OPINION

1. The rationale supporting the development of palifosfamide
2. Ifosfamide is active in STS: what does this mean for palifosfamide?
3. Phase II trial of palifosfamide suggests antitumor activity
4. Palifosfamide offers a better safety profile than ifosfamide
5. Ziopharm initiate PICASSO III pivotal trial without FDA's SPA
6. The two regulatory approval pathways
7. Is palifosfamide eligible for Accelerated Approval?
8. Is PFS a validated surrogate for overall survival in randomized front-line STS cancer trials?
9. The Votrient Precedent - Full approval based on PFS
10. Will palifosfamide succeed in the PICASSO III trial?
11. Is the MATISSE phase III trial in SCLC likely to succeed?


MARKET OPPORTUNITY

1. Revenue projection in STS
2. Revenue projections in other indications
3. Competitive landscape



CONCLUSION

Companies Mentioned


- Threshold Pharmaceuticals
- Merck KgaA
- Eisai
- Zeltia
- JNJ
- Ariad Pharmaeuticals,Glaxo-Smith Kline



For more information visit http://www.researchandmarkets.com/research/q99tkv/ziopharm

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
2. EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
3. Hoopes Vision Surgeon First in Utah to Implant New Light Adjustable Artificial Lens
4. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
5. European Interventional Cardiology Device Market Will Remain Stable Through 2022 at Over $1.2 Billion
6. Long Term Follow Up Data On WEB Aneurysm Embolization System Demonstrate High Rate Of Stable Occlusion In Difficult To Treat Aneurysms
7. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
8. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
9. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
10. Maximum-Strength Formulation Offers Highest Concentration and Purity
11. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ... markets and sells medical devices and wearable sleep ... and international markets, today announced its corporate and ... Company,s resources to develop its mobile health business, ... more on its major businesses. As of this ...
Breaking Medicine Technology:
(Date:2/8/2016)... IN (PRWEB) , ... February 08, 2016 , ... ... the Indianapolis, IN metro area, has selected the latest beneficiary of their ongoing ... organization dedicated to preventing bullying in area schools. Donations are now being accepted ...
(Date:2/8/2016)... ... 08, 2016 , ... Remember the old saying “rub some dirt on it”? ... author of “Calcium Bentonite Clay” the health benefits of integrating clay into a daily ... body. , A former motivational speaker, Perry A~ has since dedicated her life to ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... showing greater than 50% lower incidence rate of type 2 diabetes in the ... averages. ”It is time to make a change in public health,” states Carole ...
(Date:2/8/2016)... ... 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of ... of his birthday on February 10th. During this time, people can achieve better ... over 250,000 people from over 40 different countries as an “ordinary man with an ...
(Date:2/7/2016)... Michigan (PRWEB) , ... February 07, 2016 , ... Women's ... of National Wear Red Day. National Wear Red Day is the first Friday ... women. Heart disease and stroke cause 1 in 3 deaths among women each year ...
Breaking Medicine News(10 mins):